

Reference:	FOI.3961.20
Subject:	Biologic and biosimilar product prescribing in Rheumatology
Date of Request:	9 September 2020

Requested:

1. How many patients have been treated with biologics or biosimilar products in the last 12 months for the following conditions:
 - Rheumatoid Arthritis
 - Psoriatic Arthritis
 - Ankylosing Spondylitis
 - Non-Radiographic Axial Spondyloarthritis

2. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 12 months with the following drugs:
 - Abatacept [Orencia]
 - Adalimumab [Amgevita]
 - Adalimumab [Humira]
 - Adalimumab [Hyrimoz]
 - Adalimumab [Imraldi]
 - Apremilast [Otezla]
 - Baricitinib [Olumiant]
 - Certolizumab [Cimzia]
 - Etanercept [Benepali]
 - Etanercept [Enbrel]
 - Etanercept [Erelzi]
 - Golimumab [Simponi]
 - Infliximab [Flixabi]
 - Infliximab [Inflectra]
 - Infliximab [Remicade]
 - Infliximab [Remsima]
 - Ixekizumab [Taltz]
 - Rituximab [MabThera]
 - Rituximab [Rixathon]
 - Rituximab [Truxima]
 - Sarilumab [Kevzara]
 - Secukinumab [Cosentyx]
 - Tocilizumab [Ro Actemra]
 - Tofacitinib [Xeljanz]
 - Upadacitinib [Rinvoq]
 - Ustekinumab [Stelara]

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients currently being treated with biologics or biosimilar products for the rheumatology conditions listed below.

The information provided is as it is currently held, due to the system recording live data.

Condition	Number
Ankylosing spondylitis	107
Non-radiographic axial spondyloarthritis	2
Probable psoriatic arthritis	2
Psoriatic arthritis	120
Rheumatoid arthritis	478
Sero negative inflammatory arthritis	8
Sero negative rheumatoid arthritis	2
Sero positive rheumatoid arthritis	4

2. The UHB is unable to provide you with the number of rheumatology patients treated with the listed medications, as it is estimated that the cost of answering your request would exceed the “appropriate level” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004.

The “appropriate level” represents the estimated cost of one person spending 18 hours or (2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the number of patients that were prescribed the listed medications, the UHB would need to cross reference the dispensed medications with the patient records to identify the information requested.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000, which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the *appropriate limit*.

Under section 16 of the Freedom of Information Act 2000, the UHB has an obligation to provide advice and assistance. The UHB therefore provides, within the table below, the number of medications dispensed by the Homecare team for rheumatology patients. As advised in question 1, the information provided is as it is currently held, due to the system recording live data.

Medication	Number dispensed
Abatacept [Orencia]	66
Adalimumab [Amgevita]	5
Adalimumab [Humira]	21
Adalimumab [Imraldi]	128
Apremilast [Otezla]	36
Baricitinib [Olumiant]	96
Certolizumab [Cimzia]	44
Etanercept [Benepali]	215
Etanercept [Enbrel]	30
Etanercept [Erelzi]	27
Golimumab [Simponi]	20
Infliximab [Inflectra]	1
Ixekizumab [Taltz]	1
Sarilumab [Kevzara]	1

Secukinumab [Cosentyx]	36
Tocilizumab [Ro Actemra]	56
Ustekinumab [Stelara]	9

In addition, the UHB provides, within the table overleaf, the number of medications that were dispensed during the requested timeframe as recorded by the UHB's pharmacy system for all indications.

Medication	Number dispensed
Abatacept [Orencia]	90
Adalimumab [Amgevita]	15
Adalimumab [Humira]	22
Adalimumab [Hyrimoz]	0
Adalimumab [Imraldi]	146
Apremilast [Otezla]	31
Baricitinib [Olumiant]	100
Certolizumab [Cimzia]	46
Etanercept [Benepali]	243
Etanercept [Enbrel]	34
Etanercept [Erelzi]	27
Golimumab [Simponi]	22
Infliximab [Flixabi]	0
Infliximab [Inflectra]	33
Infliximab [Remicade]	0
Infliximab [Remsima]	0
Ixekizumab [Taltz]	2
Rituximab [MabThera]	0
Rituximab [Rixathon]	0
Rituximab [Truxima]	82
Sarilumab [Kevzara]	0
Secukinumab [Cosentyx]	47
Tocilizumab [Ro Actemra]	101
Tofacitinib [Xeljanz]	0
Upadacitinib [Rinvoq]	0
Ustekinumab [Stelara]	13